Novel ELANE Gene Mutation in a Korean Girl with Severe Congenital Neutropenia by Shim, Ye Jee et al.
© 2011 The Korean Academy of Medical Sciences.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) 
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
pISSN 1011-8934
eISSN 1598-6357
Novel ELANE Gene Mutation in a Korean Girl with Severe 
Congenital Neutropenia
Severe congenital neutropenia is a heterozygous group of bone marrow failure syndromes 
that cause lifelong infections. Mutation of the ELANE gene encoding human neutrophil 
elastase is the most common genetic alteration. A Korean female pediatric patient was 
admitted because of recurrent cervical lymphadenitis without abscess formation. She had 
a past history of omphalitis and isolated neutropenia at birth. The peripheral blood showed 
a markedly decreased absolute neutrophil count, and the bone marrow findings revealed 
maturation arrest of myeloid precursors at the promyelocyte to myelocyte stage. Her direct 
DNA sequencing analysis demonstrated an ELANE gene mutation (c.607G> C; p.Gly203Arg),   
but her parents were negative for it. She showed only transient response after subcutaneous 
15 μg/kg/day of granulocyte colony stimulating factor administration for six consecutive 
days. During the follow-up observation period, she suffered from subsequent seven febrile 
illnesses including urinary tract infection, septicemia, and cellulitis.
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INTRODUCTION
Severe chronic neutropenia is a congenital condition defined 
as an absolute neutrophil count (ANC) of less than 500/µL for 
at least three months (1, 2). Generally, underlying hematologic 
disorders, autoimmune diseases, viral infections, or drugs caus-
ing neutropenia should be excluded. There are three categories 
according to the onset time or pattern of variation of neutrophil 
levels: congenital, cyclic, and idiopathic. Among them, severe 
congenital neutropenia (SCN) is an inborn disorder with matu-
ration arrest of the early stage of granulopoiesis associated with 
various genetic abnormalities (3). In addition, cyclic neutrope-
nia (CN) is a related disorder characterized by periodic oscilla-
tion of the peripheral neutrophil count, with an average 21-day 
frequency (1, 2). Among several associated genetic mutations, 
the variants of the ELANE sequence comprise approximately 
50% of the genetic causes of SCN and nearly all of CN (4), and it 
is known to be correlated with more severe neutropenia and 
serious clinical manifestations in SCN (5). We herein introduce 
a Korean girl with typical features of SCN and a novel ELANE 
gene mutation.
 
CASE DESCRIPTION
A 9-month-old girl who was born on September 17th, 2009 was 
transferred to our hospital with prolonged fever and recurrent 
cervical lymphadenitis on June 25th, 2010. Her initial laboratory 
tests revealed severe neutropenia (ANC 90/µL) and increased 
acute phase reactants (erythrocyte sedimentation rate 97 mm/
hr and C-reactive protein 7.9 mg/dL). She had a past history of 
admission to the neonatal intensive care unit at another hospi-
tal at birth due to omphalitis. The ANC was also low (100/µL) at 
that time. Her course of development was normal, and she had 
no congenital malformation suggestive of specific syndromes 
associated with neutropenia. Family history was nonspecific, 
and she had no siblings.
  The cervical contrast enhanced computed tomography (CT) 
was performed to exclude abscess formation or deep neck in-
fection that would need incision or aspiration. There was no def-
inite drainable lesion (Fig. 1). Bone marrow (BM) findings showed 
early-stage maturation arrest of myelopoiesis (cellularity 80%-
100%, myeloblasts 3.0%, promyelocytes 0.7%, myelocytes 2.2%, 
metamyelocytes 0.5%, band neutrophils 0.2%, and segmented 
neutrophils 0.0%), with an M:E ratio of 0.43:1 (Fig. 2). There was Shim YJ, et al.  •  Novel ELANE Gene Mutation in Severe Congenital Neutropenia
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no evidence of malignant involvement in the BM. The chromo-
some study was normal (46, XX).
  Considering her past history and physical examination, SCN 
associated with ELANE abnormality was suspected. Direct DNA 
sequencing analysis of the ELANE gene demonstrated a substi-
tution of the 607th base (G to C) in exon 5, resulting in a change 
of the 203rd codon (glycine to arginine), which is a novel varia-
tion of SCN (c.607G > C; p.Gly203Arg) (Fig. 3). Her parents’ tests 
were negative. The primers used in sequencing were GGACTT- 
CCCAACCCTGAC (forward) and AGCCAAGGAGCATCAAA-
CAC (reverse).
  She had no increase in her ANC despite daily administration 
of subcutaneous 5-10 µg/kg granulocyte colony stimulating fac-
tor (G-CSF). After management with an increased dose (15 µg/
kg/day) of G-CSF for six consecutive days, she recovered and 
was discharged with a increased ANC (11,110/µL) (Fig. 4). How-
ever, the ANC was again decreased at 990/µL when she visited 
our outpatient clinic one week after cessation of the G-CSF in-
jections, and reduced to 130/µL after one month. She has suf-
fered subsequent seven episodes of febrile illnesses until the 
present (Table 1). All of them were managed with prompt ad-
ministration of intravenous empiric broad-spectrum antibiot-
ics, cefepime.
 
DISCUSSION
SCN is a very rare condition that is diagnosed when the ANC is 
less than 500/µL from birth, with myeloid cell differentiation 
arrest at an early stage in the BM (1, 3). Patients suffer from life-
long infections. CN is also a congenital disorder of granulopoi-
esis characterized by periodic oscillations in the number of cir-
culating neutrophils (1, 2). BM findings of patients with CN vary 
with the cycle. Patients experience infections when the neutro-
phil count drops below 500/µL and approaches zero. Both SCN 
and CN are related to an ELANE alteration associated with spo-
radic or autosomal dominant inheritance (6).
  SCN is a genetically heterozygous disease group with several 
gene mutations and various modes of inheritance (3, 7). There 
A B
Fig. 2. Microscopic examination of the bone marrow aspirate smear. (A) It revealed markedly decreased granulocytic precursors (Wright/Giemsa stain, × 400). (B) Myeloblasts 
and promyelocytes with prominent vacuolations are present, while mature neutrophils are absent (Wright/Giemsa stain, × 1,000).
Fig. 1. Contrast enhanced computed tomography of neck revealed conglomerated 
prominent enlarged lymph nodes in the internal jugular and posterior cervical chain 
(arrow). There was no drainable pus at the infection site.
A
B
C
Fig. 3. Direct DNA sequencing analysis demonstrated a novel ELANE gene mutation 
(c.607G>C; p.Gly203Arg) (arrow) (A). In the case of her parents, no mutation was de-
tected (B, C).Shim YJ, et al.  •  Novel ELANE Gene Mutation in Severe Congenital Neutropenia
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are some correlations between the mutant gene and clinical 
manifestations (7). For example, patients with the HAX1 abnor-
mality show developmental delay or epilepsy with autosomal 
recessive inheritance (Kostmann syndrome), while patients with 
the ELANE mutation, which arises sporadically or follows auto-
somal dominant inheritance, have no neurological problems. 
  The female patient we herein report showed typical clinical 
manifestations of SCN. Her diagnosis was delayed, however, un-
til nine months of age, because her past history of an umbilical 
cord infection and isolated severe neutropenia was overlooked. 
It is important to reconsider patients’ history and laboratory tests 
in the case of recurrent bacterial infections. Since the patient had 
no anomalous morphology or neurological problems, we first 
suspected the ELANE gene mutation. If the patients show any 
malformations, Fanconi anemia/Schwachman-Diamond syn-
drome (skeletal abnormality), dyskeratosis congenita (nail dys-
trophy), or Diamond-Blackfan syndrome (anomaly of face or 
hand) should be considered (8).
  Mutation of the ELANE gene (chromosome 19p13.3) encod-
ing human neutrophil elastase (NE) is the most common ge-
netic alteration in SCN (3). It comprises about 50% of SCN and 
nearly all of CN (3, 4). There have been about 50 reported ELANE 
variants in SCN and CN worldwide. There are some cases of 
Korean SCN patients, but until today, a genetically confirmed 
ELANE gene mutation was the only one in Korea (c.170C > T; 
p.Ala57Val) (9). 
  Neutrophils play a key role in innate immunity and the host’s 
defense mechanisms by phagocytosing, killing, and digesting 
bacteria and fungi (10). In particular, azurophilc (primary) gran-
ules in the neutrophil, which are formed during the promyelo-
cytic stage, contain several important proteins (myeloperoxi-
dase, cathepsin G, elastase, proteinase 3, bactericidal/permea-
bility-increasing protein, and defensin) essential for antibacte-
rial activity. Among them, NE attacks gram negative bacteria like 
Klebsiella pneumoniae or Escherichia coli (11). In neutrophils in 
which NE is inactivated, bacteria escape from the phagosome, 
resulting in increase of bacterial survival (12). Although the en-
tire pathophysiology of how the ELANE mutation develops in 
neutropenia is unknown, recently it is believed that the mutant 
NE tends to be misfolded, which leads to apoptosis of myeloid 
progenitor cells through an ‘unfolded protein response’ by the 
endoplasmic reticulum (13).
  For those reasons, there are few mature neutrophils, while 
promyelocytes are normally present; that is the so-called ‘mat-
uration arrest’ in the BM, and thus patients suffer from lifelong 
infections in SCN. Morphologically prominent vacuolations or 
aberrations of azurophilc granules may appear in the BM (7). 
Infections include bacterial illnesses, such as a urinary tract in-
fection, pneumonia, omphalitis, septicemia, lymphadenitis, oti-
tis media, cellulitis, and fungal disease like oral thrush.
  Neutrophils contribute to tissue injury and reconstitution as 
well as play a role in host-defense cells (14). Thus, absence of 
pus at infection sites is the characteristic feature of SCN, as dem-
onstrated by the neck CT of the patient in this study (7).
  As a treatment of choice, the Severe Chronic Neutropenia In-
ternational Registry recommends that the G-CSF injection is 
started at a dose of 5 µg/kg/day and continued in upward 2-fold 
adjustments until the ANC reaches over 1,000-1,500/µL (15). 
Generally, SCN patients require a higher dose of G-CSF (medi-
an 7.3-23.0 µg/kg/day, maximum 242.4 µg/kg/day) compared 
to cyclic or idiopathic neutropenia patients. About 90% of SCN 
patients respond to G-CSF treatment, but the remainder have 
only a temporary or no response to G-CSF (16). Although the 
predictors of poor response are not yet demonstrated, most re-
fractory cases have very low initial ANC levels. In addition, the 
ELANE gene mutation is known to be associated with more se-
vere neutropenia and serious clinical manifestations in SCN (5).
Table 1. Febrile episodes and respective etiologic pathogens after she was confirmed as severe congenital neutropenia with ELANE gene mutation
No. Age (months) ANC (/µL) ESR (mm/hr) CRP (mg/dL) Cause of fever Cultured organism
1 14 130 43 13.3 Unknown -
2 15 140 64 17.8 Urinary tract infection Enterococcus faecium
3 17 190 41   0.5 Unknown -
4 19 140 20   0.8 Septicemia Escherichia coli
5 21 260 36   7.2 Unknown -
6 22 260 58 10.8 Unknown -
7 24 250 62   4.7 Cellulitis Pseudomonas aeruginosa
ANC, absolute neutrophil count; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein.
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Fig. 4. Change in the peripheral blood count after daily subcutaneous injections of 
15 µg/kg of G-CSF (arrows). ANC, absolute neutrophil count; WBC, white blood cells.Shim YJ, et al.  •  Novel ELANE Gene Mutation in Severe Congenital Neutropenia
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  Although septic mortality is markedly decreased by G-CSF 
treatment, the cumulative incidence of myelodysplastic syn-
drome (MDS) or acute myeloid leukemia (AML) in SCN is about 
20% after 10 yr treatment (17). It is controversial whether SCN is 
an obvious precancerous condition, or the G-CSF treatment con-
tributes to evolution to MDS/AML. Considering that cyclic or 
idiopathic neutropenia patients do not develop MDS/AML in 
spite of G-CSF administration, and refractory SCN patients who 
were exposed to a higher dose of G-CSF tend to develop MDS/
AML, a combination of both theories is also possible. In the case 
of non-responders, stem cell transplantation from an HLA-iden-
tical sibling is the optimal therapeutic modality (8, 18).
  In this case, the patient showed only temporary response to 
subcutaneous 15 µg/kg/day of G-CSF for six consecutive days. 
We have not yet increased the dose of G-CSF due to a financial 
problem associated with standards of Korean medical insurance. 
To control infections, we selected the 4th generation cephalo-
sporine (cefepime) empirically to cover both Gram positive and 
negative bacteria including Pseudomonas aeruginosa. Total seven 
febrile episodes were successfully treated without complication 
by immediate intravenous antibiotic therapy. There has been 
no evidence of fungal infection or MDS/AML yet. Since she has 
no siblings and is very young, we closely follow her, with the idea 
of stem cell transplantation in reserve.
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